GlassScriptPhysician profile
Ali R Davis
NPI 1194847947
$1,682.26
in general payments reported to CMS, 2019-2025
22 companies · $319 in 2025
The $319 reported for 2025 was less than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $117 · 2020: $33.62 · 2021: $61.93 · 2022: $342 · 2023: $422 · 2024: $386 · 2025: $319.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,128.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,127.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $271.77 | 2023-2025 | Jublia, Cabtreo |
| Nevro Corp. | $234.77 | 2022-2023 | Senza |
| Paratek Pharmaceuticals, INC. | $232.18 | 2022-2025 | Nuzyra |
| Stryker Corporation | $194.41 | 2023-2024 | Infinity, Viaflow, N/A |
| Organogenesis INC. | $111.37 | 2019-2024 | |
| Surgenex LLC | $104.45 | 2025 | Ardeograft, Pellograft, Surmatrix |
| Abbvie INC. | $87.78 | 2022-2024 | Dalvance |
| Ibsa Pharma INC. | $60.81 | 2023-2024 | Tirosint, Licart, Licart |
| Melinta Therapeutics, LLC | $46.39 | 2019-2024 | Orbactiv, Kimyrsa |
| Convatec INC. | $43.76 | 2024-2025 | |
| Averitas Pharma INC. | $40.64 | 2023 | Qutenza |
| Acumed LLC | $30.77 | 2024 | Acumed, Osteomed |
| Janssen Pharmaceuticals, INC | $30.60 | 2021 | |
| Zimmer Biomet Holdings, INC. | $30.31 | 2019 | |
| Wright Medical Technology, INC. | $27.81 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nabriva Therapeutics, Plc | $25.80 | 2022 | |
| Treace Medical Concepts, INC. | $25.54 | 2025 | |
| Kerecis Limited | $21.62 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Bioventus LLC | $20.36 | 2022 | |
| Smith+Nephew, INC. | $14.52 | 2022 | |
| Depuy Synthes Sales INC. | $13.35 | 2023 | Motoband |
| Arbor Pharmaceuticals, INC. | $13.25 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.